Sansure Biotech Inc. (SHA:688289)
China
· Delayed Price · Currency is CNY 19.92
-0.15 (-0.75%)
May 14, 2025, 2:44 PM CST
Sansure Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | May '25 May 13, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Market Capitalization | 11,443 | 13,001 | 11,187 | 12,747 | 23,600 | 45,580 | Upgrade
|
| Market Cap Growth | 12.05% | 16.22% | -12.24% | -45.99% | -48.22% | - | Upgrade
|
| Enterprise Value | 7,877 | 8,982 | 6,408 | 7,417 | 18,716 | 41,873 | Upgrade
|
| Last Close Price | 19.93 | 22.70 | 19.05 | 20.60 | 35.84 | 68.02 | Upgrade
|
| PE Ratio | 43.40 | 50.19 | 30.76 | 6.58 | 10.52 | 17.42 | Upgrade
|
| Forward PE | 30.20 | 8.19 | 8.19 | 8.19 | 12.20 | 13.61 | Upgrade
|
| PS Ratio | 7.24 | 8.69 | 11.11 | 1.98 | 5.23 | 9.57 | Upgrade
|
| PB Ratio | 1.54 | 1.77 | 1.51 | 1.70 | 3.70 | 9.61 | Upgrade
|
| P/TBV Ratio | 1.89 | 1.89 | 1.62 | 1.72 | 3.73 | 9.67 | Upgrade
|
| P/FCF Ratio | - | - | - | 6.37 | 15.69 | 17.99 | Upgrade
|
| P/OCF Ratio | - | - | 256.93 | 4.98 | 12.57 | 17.25 | Upgrade
|
| EV/Sales Ratio | 4.98 | 6.00 | 6.36 | 1.15 | 4.15 | 8.79 | Upgrade
|
| EV/EBITDA Ratio | - | 24.71 | 81.60 | 3.27 | 7.28 | 13.52 | Upgrade
|
| EV/EBIT Ratio | 29.50 | 34.04 | - | 3.38 | 7.41 | 13.64 | Upgrade
|
| EV/FCF Ratio | - | - | - | 3.71 | 12.44 | 16.53 | Upgrade
|
| Debt / Equity Ratio | 0.11 | 0.06 | 0.01 | 0.00 | 0.00 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | - | 1.20 | 0.41 | 0.01 | 0.01 | 0.02 | Upgrade
|
| Debt / FCF Ratio | - | - | - | 0.01 | 0.01 | 0.02 | Upgrade
|
| Asset Turnover | 0.17 | - | 0.11 | 0.79 | 0.72 | 1.56 | Upgrade
|
| Inventory Turnover | 0.10 | - | 0.77 | 8.04 | 3.97 | 5.69 | Upgrade
|
| Quick Ratio | 4.07 | - | 5.98 | 4.48 | 8.29 | 6.91 | Upgrade
|
| Current Ratio | 4.44 | - | 6.47 | 4.79 | 8.99 | 7.38 | Upgrade
|
| Return on Equity (ROE) | 3.56% | 3.51% | 4.66% | 27.88% | 40.31% | 98.69% | Upgrade
|
| Return on Assets (ROA) | 1.81% | - | -0.15% | 16.86% | 25.17% | 62.94% | Upgrade
|
| Return on Capital (ROIC) | 2.06% | 2.16% | -0.18% | 19.68% | 28.20% | 71.62% | Upgrade
|
| Return on Capital Employed (ROCE) | 3.20% | - | - | 28.90% | 39.30% | 64.40% | Upgrade
|
| Earnings Yield | 2.36% | 1.99% | 3.25% | 15.19% | 9.50% | 5.74% | Upgrade
|
| FCF Yield | - | - | -3.11% | 15.69% | 6.37% | 5.56% | Upgrade
|
| Dividend Yield | 1.99% | - | 2.43% | 6.30% | 2.12% | 1.12% | Upgrade
|
| Payout Ratio | - | - | 110.10% | 33.92% | 19.61% | 11.51% | Upgrade
|
| Buyback Yield / Dilution | -1.04% | -0.35% | -0.26% | 0.59% | -6.55% | -3.97% | Upgrade
|
| Total Shareholder Return | 0.95% | -0.35% | 2.17% | 6.90% | -4.43% | -2.85% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.